Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Trebananib in Advanced Solid Tumors
NCT03239145Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2018
- Primary completion
- Dec 2024
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of trebananib in solid tumor, melanoma, ovarian cancer and 2 more (5 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Dose Limiting Toxicities at 3 weeks, Maximum Tolerated Dose at 3 weeks and 1 more. Started May 2018; status: completed.
02
Drugs
trebananib
03
Conditions
solid tumormelanomaovarian cancerrenal cell carcinoma (RCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03239145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239145.